Article

Retinopathy a marker for systemic disease morbidity, mortality in diabetics

Diabetic patients with severe retinopathy should be carefully followed and treated for renal and cardiovascular disease, according to Ronald Klein, MD, MPH, who spoke during the "Ocular Pathology&#8212Beyond the Eye" symposium at the Association for Research in Vision and Ophthalmology annual meeting.

May 2 - Fort Lauderdale, FL - Diabetic patients with severe retinopathy should be carefully followed and treated for renal and cardiovascular disease, according to Ronald Klein, MD, MPH, who spoke during the "Ocular Pathology-Beyond the Eye" symposium at the Association for Research in Vision and Ophthalmology annual meeting.

Early studies by Berkow, Caird, and Davis in the 1960s and 1970s showed that retinopathy severity was associated with an increased risk of mortality in patients with diabetes. In a more recent study, diabetic patients with severe retinopathy have been shown to be at increased risk for diabetic nephropathy and ischemic heart disease leading to death, said Dr. Klein, who presented results of the Wisconsin Epidemiological Study of Diabetic Retinopathy.

This large population study followed almost 3,000 patients with type 1 and 2 diabetes over a 15-year period. In the type I diabetes group, individuals with severe retinopathy were found to have uncontrolled hypertension, dyslipidemia, diabetic nephropathy, and history of heart attack. In the type II diabetes group, severe retinopathy was associated with nephropathy.

"Diabetic patients with moderate retinopathy should be examined frequently by their primary care physicians to detect and treat elevated blood pressure, early renal disease, and cardiovascular disease," said Dr. Klein of the University of Wisconsin, Madison.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.